Clinical evidence has shown that blockade of the PD-1/PD-L1 pathway and Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4) leads to sustained anti-tumor responses, significantly altering treatment outcomes in advanced and metastatic cancers. This evidence concerns the gene CTLA4 and metastatic malignant neoplasm.